| Greg R Smith, NP | |
|
600 S 3rd St, Gadsden, AL 35901-5304 | |
| (256) 543-5390 | |
| Not Available |
| Full Name | Greg R Smith |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Family |
| Location | 600 S 3rd St, Gadsden, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215966569 | NPI | - | NPPES |
| 891011090 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 1-061723 (Alabama) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 1-061723 (Alabama) | Primary |
| Entity Name | Paragon Contracting Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225071459 PECOS PAC ID: 3971417825 Enrollment ID: O20050218000756 |
News Archive
Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.
Combining a wealth of information derived from previous studies with data from more than 500 patients, an international team led by researchers from Johns Hopkins has developed a computer-based set of rules that more accurately predicts when patients with a rare heart condition might benefit-or not-from lifesaving implanted defibrillators.
Loyola Medicine physicians have proposed a simple new system to improve the reporting of robotic surgeries performed by surgeons in training.
Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.
› Verified 1 days ago
| Entity Name | Island Medical Alabama Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104097666 PECOS PAC ID: 3072682103 Enrollment ID: O20080515000492 |
News Archive
Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.
Combining a wealth of information derived from previous studies with data from more than 500 patients, an international team led by researchers from Johns Hopkins has developed a computer-based set of rules that more accurately predicts when patients with a rare heart condition might benefit-or not-from lifesaving implanted defibrillators.
Loyola Medicine physicians have proposed a simple new system to improve the reporting of robotic surgeries performed by surgeons in training.
Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.
› Verified 1 days ago
| Entity Name | App Of Alabama Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659646040 PECOS PAC ID: 3577725068 Enrollment ID: O20120430000174 |
News Archive
Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.
Combining a wealth of information derived from previous studies with data from more than 500 patients, an international team led by researchers from Johns Hopkins has developed a computer-based set of rules that more accurately predicts when patients with a rare heart condition might benefit-or not-from lifesaving implanted defibrillators.
Loyola Medicine physicians have proposed a simple new system to improve the reporting of robotic surgeries performed by surgeons in training.
Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.
› Verified 1 days ago
| Entity Name | Aspire Health Medical Partners Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124443403 PECOS PAC ID: 9931332111 Enrollment ID: O20150324002614 |
News Archive
Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.
Combining a wealth of information derived from previous studies with data from more than 500 patients, an international team led by researchers from Johns Hopkins has developed a computer-based set of rules that more accurately predicts when patients with a rare heart condition might benefit-or not-from lifesaving implanted defibrillators.
Loyola Medicine physicians have proposed a simple new system to improve the reporting of robotic surgeries performed by surgeons in training.
Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.
› Verified 1 days ago
| Entity Name | Nes Tennessee, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437606605 PECOS PAC ID: 3678472040 Enrollment ID: O20161031002328 |
News Archive
Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.
Combining a wealth of information derived from previous studies with data from more than 500 patients, an international team led by researchers from Johns Hopkins has developed a computer-based set of rules that more accurately predicts when patients with a rare heart condition might benefit-or not-from lifesaving implanted defibrillators.
Loyola Medicine physicians have proposed a simple new system to improve the reporting of robotic surgeries performed by surgeons in training.
Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Greg R Smith, NP 200 Corporate Blvd, Lafayette, LA 70508-3870 Ph: (800) 893-9698 | Greg R Smith, NP 600 S 3rd St, Gadsden, AL 35901-5304 Ph: (256) 543-5390 |
News Archive
Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.
Combining a wealth of information derived from previous studies with data from more than 500 patients, an international team led by researchers from Johns Hopkins has developed a computer-based set of rules that more accurately predicts when patients with a rare heart condition might benefit-or not-from lifesaving implanted defibrillators.
Loyola Medicine physicians have proposed a simple new system to improve the reporting of robotic surgeries performed by surgeons in training.
Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.
› Verified 1 days ago